An analysis of COVID-19 clinical outcomes among people taking ACE inhibitor or ARB monotherapy vs. combination therapy could provide valuable observational data on the potential benefits of combination therapy in reducing susceptibility or severity of COVID-19. This evidence concerns the gene ACE and COVID-19.